Appendix Table 8.

Efficient colonoscopy screening strategies among transplant Cystic Fibrosis patients (assuming 5-fold and 10-fold increased rates of cardiovascular complications).

	Outcomes per 1,000 transplant cystic fibrosis individuals free of diagnosed cancer at age 30 years in 2017 (with organ transplant at age 30, 3% discounted)
	Screening tests		Surveillance COLs	Total COLs	Compli -cations	CRC Casesc	CRC deatha,c	LY with CRC	LYGb	Total costs (*$1,000)	Net costs (*$1,000)	Reductionsb (%)		ICER (*$1,000)
	FIT	COLs										CRC incidencec	CRC mortalityc
Colonoscopy strategies (5-fold increased rates of cardiovascular complications)
No screening	0	0	0	30	0	52	22	115	0	2065435	0	0	0	-
COL 45–55 y, 10 y	0	199	342	553	4	39	10	139	28	2452010	386576	25	57	2
COL 45–55 y, 5 y	0	200	343	554	4	39	9	139	28	2452589	387154	25	57	8
COL 40–55 y, 5 y	0	324	591	923	6	34	7	129	42	2618834	553399	36	70	12
COL 35–55 y, 5 y	0	607	838	1451	7	31	5	122	51	3049189	983754	41	77	46
COL 35–55 y, 3 y	0	642	1265	1912	8	26	4	110	56	3373257	1307822	49	82	75
COL 30–55 y, 3 y	0	1511	1825	3339	10	25	3	99	63	4652949	2587514	53	86	177
Colonoscopy strategies (10-fold increased rates of cardiovascular complications)
No screening	0	0	0	30	0	52	22	115	0	2066410	0	0	0	-
COL 45–55 y, 10 y	0	199	341	553	7	39	10	139	28	2469059	402648	25	57	3
COL 45–55 y, 5 y	0	200	342	554	7	39	10	139	28	2469686	403276	25	57	10
COL 40–55 y, 5 y	0	324	591	923	9	34	7	129	42	2641176	574766	36	70	14
COL 35–55 y, 5 y	0	607	838	1451	11	31	5	122	51	3075548	1009138	41	76	49
COL 35–55 y, 3 y	0	642	1265	1911	13	26	4	110	55	3406590	1340180	49	81	85
COL 30–55 y, 3 y	0	1511	1825	3339	16	25	3	99	62	4691373	2624962	53	85	194

COL indicates colonoscopy; CRC, colorectal cancer; FIT = Fecal Immunochemical Test; LY, Life-years; LYG, LY gained compared with no screening; ICER, Incremental cost-effectiveness ratio (Costs/LYs gained).

^aIncluding deaths from complications of screening;

^bcompared with no screening;

^cCRC cases and CRC death were not discounted.

Bold rows indicate optimal screening strategies.